liraglutide

Liraglutide (Liraglutida) is a synthetic analog of glucagon-like peptide-1 (GLP-1), an agonist of the GLP-1 receptor. Liraglutide can be used to treat type 2 diabetes and chronic obesity.

Liraglutide-D8 tetraTFA is the deuterated form of Liraglutide. Liraglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and is utilized in the study of type 2 diabetes.

Liraglutide-13C6,15N trifluoroacetic acid is a version of Liraglutide labeled with 13C and 15N. Liraglutide trifluoroacetic acid (T6876) acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and is clinically used for the treatment of type 2 diabetes.

Liraglutide acetate is the acetate salt form of Liraglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist, utilized in the study of type 2 diabetes.

Liraglutide (TFA) is an agonist of the glucagon-like peptide 1 receptor (GLP-1). It activates GLP-1, leading to insulin secretion when glucose levels are elevated. Additionally, Liraglutide (TFA) reduces glucagon secretion in a glucose-dependent manner. This compound is utilized in research related to type 2 diabetes.

Liraglutide sodium salt (204656-20-2, free base) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of endogenous incretins, promoting glucose-dependent insulin secretion, inhibiting glucagon release, and delaying gastric emptying. Liraglutide sodium salt (204656-20-2, free base) is commonly used in research related to type 2 diabetes, obesity, and metabolic disorders.

Liraglutide-13C5,15N trifluoroacetic acid is a version of Liraglutide labeled with 13C and 15N isotopes. Liraglutide trifluoroacetic acid (T6876) is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is clinically used for the treatment of type 2 diabetes.

MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.

Pal-Glu(OSu)-OH, a side chain specific to Liraglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used in type 2 diabetes mellitus research.

CTX-1211 is a selective and orally active melanocortin 4 receptor (MC4R) agonist with an EC50 of 0.38 nM. It enhances the effects of liraglutide in suppressing food intake and promoting weight loss, supporting anorectic and weight-reducing activities. CTX-1211 is primarily employed in research related to obesity and other metabolic disorders.

Pal-Glu(OSu)-OtBu (Palmitoyl-Glu(OSu)-OBut) is a crucial intermediate in the synthesis of the compound Liraglutide.